Literature DB >> 24262797

Nephropathy and elevated BP in mice with podocyte-specific NADPH oxidase 5 expression.

Chet E Holterman1, Jean-François Thibodeau, Chelsea Towaij, Alex Gutsol, Augusto C Montezano, Robin J Parks, Mark E Cooper, Rhian M Touyz, Christopher R J Kennedy.   

Abstract

NADPH oxidase (Nox) enzymes are a significant source of reactive oxygen species, which contribute to glomerular podocyte dysfunction. Although studies have implicated Nox1, -2, and -4 in several glomerulopathies, including diabetic nephropathy, little is known regarding the role of Nox5 in this context. We examined Nox5 expression and regulation in kidney biopsies from diabetic patients, cultured human podocytes, and a novel mouse model. Nox5 expression increased in human diabetic glomeruli compared with nondiabetic glomeruli. Stimulation with angiotensin II upregulated Nox5 expression in human podocyte cultures and increased reactive oxygen species generation. siRNA-mediated Nox5 knockdown inhibited angiotensin II-stimulated production of reactive oxygen species and altered podocyte cytoskeletal dynamics, resulting in an Rac-mediated motile phenotype. Because the Nox5 gene is absent in rodents, we generated transgenic mice expressing human Nox5 in a podocyte-specific manner (Nox5(pod+)). Nox5(pod+) mice exhibited early onset albuminuria, podocyte foot process effacement, and elevated systolic BP. Subjecting Nox5(pod+) mice to streptozotocin-induced diabetes further exacerbated these changes. Our data show that renal Nox5 is upregulated in human diabetic nephropathy and may alter filtration barrier function and systolic BP through the production of reactive oxygen species. These findings provide the first evidence that podocyte Nox5 has an important role in impaired renal function and hypertension.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24262797      PMCID: PMC3968494          DOI: 10.1681/ASN.2013040371

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  54 in total

1.  Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice.

Authors:  Hui John Zhao; Suwan Wang; Huifang Cheng; Ming-zhi Zhang; Takamune Takahashi; Agnes B Fogo; Matthew D Breyer; Raymond C Harris
Journal:  J Am Soc Nephrol       Date:  2006-09-13       Impact factor: 10.121

2.  Nicotinamide adenine dinucleotide phosphate reduced oxidase 5 (Nox5) regulation by angiotensin II and endothelin-1 is mediated via calcium/calmodulin-dependent, rac-1-independent pathways in human endothelial cells.

Authors:  Augusto C Montezano; Dylan Burger; Tamara M Paravicini; Andreia Z Chignalia; Hiba Yusuf; Mahmoud Almasri; Ying He; Glaucia E Callera; Gang He; Karl-Heinz Krause; David Lambeth; Mark T Quinn; Rhian M Touyz
Journal:  Circ Res       Date:  2010-03-25       Impact factor: 17.367

3.  Synergistic effect of mechanical stretch and angiotensin II on superoxide production via NADPH oxidase in vascular smooth muscle cells.

Authors:  Hirofumi Hitomi; Toshiki Fukui; Kumiko Moriwaki; Keisuke Matsubara; Guang-Ping Sun; Matlubur Rahman; Akira Nishiyama; Hideyasu Kiyomoto; Shoji Kimura; Koji Ohmori; Youichi Abe; Masakazu Kohno
Journal:  J Hypertens       Date:  2006-06       Impact factor: 4.844

4.  Expression and functional significance of NADPH oxidase 5 (Nox5) and its splice variants in human blood vessels.

Authors:  Deepesh Pandey; Anand Patel; Vijay Patel; Feng Chen; Jin Qian; Yusi Wang; Scott A Barman; Richard C Venema; David W Stepp; R Daniel Rudic; David J R Fulton
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-16       Impact factor: 4.733

5.  Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney.

Authors:  Eun Ah Lee; Ji Yeon Seo; Zongpei Jiang; Mi Ra Yu; Min Kyung Kwon; Hunjoo Ha; Hi Bahl Lee
Journal:  Kidney Int       Date:  2005-05       Impact factor: 10.612

6.  Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB.

Authors:  Maristela Lika Onozato; Akihiro Tojo; Atsuo Goto; Toshiro Fujita; Christopher S Wilcox
Journal:  Kidney Int       Date:  2002-01       Impact factor: 10.612

7.  Redox dependence of glomerular epithelial cell hypertrophy in response to glucose.

Authors:  Nam-Ho Kim; Hernan Rincon-Choles; Basant Bhandari; Goutam Ghosh Choudhury; Hanna E Abboud; Yves Gorin
Journal:  Am J Physiol Renal Physiol       Date:  2005-10-18

8.  Nox4 mediates angiotensin II-induced activation of Akt/protein kinase B in mesangial cells.

Authors:  Yves Gorin; Jill M Ricono; Nam-Ho Kim; Basant Bhandari; Goutam Ghosh Choudhury; Hanna E Abboud
Journal:  Am J Physiol Renal Physiol       Date:  2003-08

Review 9.  Mouse models of diabetic nephropathy.

Authors:  Frank C Brosius; Charles E Alpers; Erwin P Bottinger; Matthew D Breyer; Thomas M Coffman; Susan B Gurley; Raymond C Harris; Masao Kakoki; Matthias Kretzler; Edward H Leiter; Moshe Levi; Richard A McIndoe; Kumar Sharma; Oliver Smithies; Katalin Susztak; Nobuyuki Takahashi; Takamune Takahashi
Journal:  J Am Soc Nephrol       Date:  2009-09-03       Impact factor: 10.121

10.  Role of Nox4 in murine models of kidney disease.

Authors:  Andrea Babelova; Despina Avaniadi; Oliver Jung; Christian Fork; Janet Beckmann; Judith Kosowski; Norbert Weissmann; Narayana Anilkumar; Ajay M Shah; Liliana Schaefer; Katrin Schröder; Ralf P Brandes
Journal:  Free Radic Biol Med       Date:  2012-06-27       Impact factor: 7.376

View more
  53 in total

Review 1.  The pathobiology of diabetic vascular complications--cardiovascular and kidney disease.

Authors:  Stephen P Gray; Karin Jandeleit-Dahm
Journal:  J Mol Med (Berl)       Date:  2014-04-01       Impact factor: 4.599

2.  Endothelial or vascular smooth muscle cell-specific expression of human NOX5 exacerbates renal inflammation, fibrosis and albuminuria in the Akita mouse.

Authors:  Jay C Jha; Aozhi Dai; Chet E Holterman; Mark E Cooper; Rhian M Touyz; Chris R Kennedy; Karin A M Jandeleit-Dahm
Journal:  Diabetologia       Date:  2019-06-20       Impact factor: 10.122

Review 3.  Diabetes and Kidney Disease: Role of Oxidative Stress.

Authors:  Jay C Jha; Claudine Banal; Bryna S M Chow; Mark E Cooper; Karin Jandeleit-Dahm
Journal:  Antioxid Redox Signal       Date:  2016-04-01       Impact factor: 8.401

Review 4.  Angiotensin II and vascular injury.

Authors:  Augusto C Montezano; Aurelie Nguyen Dinh Cat; Francisco J Rios; Rhian M Touyz
Journal:  Curr Hypertens Rep       Date:  2014-06       Impact factor: 5.369

Review 5.  Enzymatic regulation and functional relevance of NOX5.

Authors:  Feng Chen; Yusi Wang; Scott Barman; David J R Fulton
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 6.  Oxidative Stress and Hypertensive Diseases.

Authors:  Roxana Loperena; David G Harrison
Journal:  Med Clin North Am       Date:  2016-10-27       Impact factor: 5.456

Review 7.  Oxidative Stress in Atherosclerosis.

Authors:  Ajoe John Kattoor; Naga Venkata K Pothineni; Deepak Palagiri; Jawahar L Mehta
Journal:  Curr Atheroscler Rep       Date:  2017-09-18       Impact factor: 5.113

8.  APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db/db mice from renal injury.

Authors:  Jin Joo Cha; Hye Sook Min; Ki Tae Kim; Jung Eun Kim; Jung Yeon Ghee; Hyun Wook Kim; Ji Eun Lee; Jee Young Han; Gayoung Lee; Hun Joo Ha; Yun Soo Bae; Sae Rom Lee; Sung Hwan Moon; Sung Chan Lee; Ganghyun Kim; Young Sun Kang; Dae Ryong Cha
Journal:  Lab Invest       Date:  2017-02-06       Impact factor: 5.662

Review 9.  NADPH oxidases and oxidase crosstalk in cardiovascular diseases: novel therapeutic targets.

Authors:  Yixuan Zhang; Priya Murugesan; Kai Huang; Hua Cai
Journal:  Nat Rev Cardiol       Date:  2019-10-07       Impact factor: 32.419

Review 10.  The future of diabetic kidney disease management: what to expect from the experimental studies?

Authors:  Federica Barutta; Stefania Bellini; Beatrice Corbetta; Marilena Durazzo; Gabriella Gruden
Journal:  J Nephrol       Date:  2020-03-27       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.